EKF DIAGNOSTICS HOLDINGS PLC - Interim results for the six months ended 30 June 2026

EKF Diagnostics Holdings PLC’s H1 2026 investor update highlights resilient financial performance, improved margins and continued progress against its five-year growth strategy. Group revenue was broadly stable at £25 million, while gross margin increased by 2.8 percentage points to 53%, adjusted EBITDA rose 2.4% to £5.9 million and basic EPS increased 26%. The Group ended the period with £16 million of cash and has returned more than £5 million to shareholders through its share buyback programme. Point-of-care revenue declined 3% to £15 million, primarily due to tender and production timing, with management emphasising that deferred orders are supported by a strong H2 order book. Life Sciences revenue grew 8% to £10 million, supported by 20% growth in contract manufacturing and fermentation. EKF continues to invest in commercial capacity, production infrastructure and product development, including a planned 30% expansion of its haemoglobin control production line and a new sensor production line. Strategic progress includes the Blood Centres of America agreement, three US blood banks now live with DiaSpect and further sites expected in H2, alongside 106% growth in BHB revenue during the first half. The acquisition of Beat Insight strengthens the sports performance portfolio through mobile and AI-enabled lactate threshold testing, while the Nexus Bioworks rebrand is designed to sharpen the positioning of the Life Sciences offering. With a target of revenues above £80 million and adjusted EBITDA above £20 million by 2029, management remains confident in a return to point-of-care growth, double-digit BHB growth and delivery of full-year 2026 expectations.